Germany's MorphoSys forms antibody therapies alliance with Daiichi Sankyo of Japan
Sankyo Co, a subsidiary of Japan's Daiichi Sankyo, is to collaborate with MorphoSys in Frankfurt an initial therapeutic antibody programme for a two-year term with the option of an extension of up to three more years.
Sankyo Co, a subsidiary of Japan's Daiichi Sankyo, is to collaborate with MorphoSys in Frankfurt an initial therapeutic antibody programme for a two-year term with the option of an extension of up to three more years.
The deal gives Daiichi Sankyo access to the MorphoSys HuCAL GOLD library at its research site in Tokyo. This technology is a new concept for the in vitro generation of highly specific and fully human antibodies suited to a range of purposes from target validation to drug development. MorphoSys will also apply the technology to generate antibodies against a target provided by Daiichi Sankyo.
Daiichi Sankyo is to carry out any preclinical and clinical development, and marketing of any resulting products, while MorphoSys will receive an upfront payment and research funding, licensing and milestone payments, plus royalties.